Project Grant R41DA053081

This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) provides $318,257 to Cari Health, Inc. to develop a therapeutic monitoring system (TMS) for remote medication compliance tracking of methadone treatment for opioid use disorder (OUD). The key products and services to be delivered include: 1) Integrating an electrochemical sensor, microneedle array, and data pipeline into a prototype wearable...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will pilot an innovative digital Contingency Management (CM) treatment delivered via mobile device to Medicaid beneficiaries with co-occurring opioid and alcohol use disorders. The $390,000 award, spanning from September 2024 to August 2027, aims to: 1) identify optimal approaches to engage Medicaid beneficiaries in digital CM through Medicaid claims data...

This Project Grant award of $594,122, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development and testing of telehealth workflows and technologies to increase access to buprenorphine treatment for opioid use disorder in vulnerable settings. The award recipient, Boulder Care, Inc., will partner with Sano Health and the National Survivors Union to provide smartphones and connectivity to people in high-risk...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $319,000 to Sano Healthcare Consultants, LLC for the development of a novel liquid methadone dispensing device and smart container system. The project aims to address key barriers in accessing medication for opioid use disorder (MOUD) by creating a low-cost, single-device solution that enables remote supervised use, telehealth, and behavioral...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $348,756 to the University of Oklahoma Health Sciences Center to develop a mobile health (mHealth) intervention that provides psychosocial and self-management support to postpartum individuals recovering from opioid use disorder (OUD). The intervention, grounded in acceptance and commitment therapy (ACT) principles, will be iteratively developed...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $400,000 to Mountainpass Technology LLC to develop, refine, and evaluate a customized version of their "MyTrials" integrated remote biomarker capture system for decentralized clinical trials (DCTs) focused on substance use disorders (SUDs). The project aims to address key methodological limitations of DCTs for SUDs by creating a product...

This federal Project Grant award of $1,422,000 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting the development and pilot testing of a mobile health (mHealth) intervention to reduce substance use and HIV risk among young adult women affected by sex trafficking. The project aims to adapt an existing mHealth intervention for this population, using qualitative and ecological momentary assessment methods to understand...

The National Institute on Drug Abuse (NIDA) awarded a $770,751 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Oregon Health & Science University (OHSU) with a period of performance from July 1, 2025 to March 31, 2030. The grant supports research to examine the impact of telehealth expansion on access to and utilization of opioid use disorder (OUD) treatment within community health centers (CHCs). The study will use over 10 years of electronic health...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,930,360 to evaluate the real-world effectiveness of telehealth-delivered buprenorphine (tele-buprenorphine) for treating opioid use disorder (OUD). The study will use national data from the Veterans Health Administration and Medicaid to compare the effectiveness of tele-buprenorphine to in-person care, including for high-risk and high-need...

The National Institute on Drug Abuse (NIDA) awarded a $445,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The grant will fund the development and pilot testing of a novel telehealth and mobile health intervention called MOMENT-V to address cannabis use disorder in young adults seen in primary care. The intervention combines motivational enhancement therapy delivered via...